Document is current
Any future updates will be listed below
-
Authors
Hasegawa, H.
Teramura, K.
Park, Y.
Ito, M.
- License Information
-
More Information
Article History
Received: 30 January 2025
Accepted: 24 April 2025
First Online: 6 June 2025
Declarations
:
: This development was undertaken under the joint research agreement between the National Cancer Center and EBM Corporation, and between the National Cancer Center and Johnson & Johnson K. K. Medical Company. H.H., K.T., and M.I. received COLOMASTER from EBM Corporation. H.H., K.T., and M.I. received devices from the Johnson & Johnson K. K. Medical Company. H.H. and M.I. received honoraria for lectures from the Johnson & Johnson K. K. Medical Company. K.T. has no conflict of interest or financial ties to disclose. Y.P. is the representative director and sole shareholder (100%) of EBM Corporation. M.I. has a patent royalty contract with EBM Corporation.
